Phosphagen™ has held a legacy position in the supplement market since its 1993 debut under Experimental and Applied Sciences, a subsidiary now owned by Hi-Tech. The company positions the product as a "gold standard" due to a synthesis process that achieves 99.99% purity, significantly higher than the 97–99% purity typical of generic supplements. This refined manufacturing cycle limits common impurities such as creatinine, dicyandiamide, and dihydrotriazine.
Hi-Tech Pharmaceuticals Scales Production to Meet Creatine Demand
Norcross-based Hi-Tech Pharmaceuticals is expanding its manufacturing capacity for Phosphagen™, the company’s flagship creatine monohydrate brand. As consumer interest in sports nutrition shifts toward high-purity supplements, the firm is upgrading its facilities to address supply shortages and capitalize on the growing demand for premium-grade creatine.
CEO Jared Wheat stated that the investment aims to leverage the company’s status as a quality leader in the premium segment, driving profitable growth. The expansion comes as market interest in creatine widens beyond professional athletics. Research into longevity, cognitive health, and neuroprotection is broadening the consumer base, putting pressure on existing supply chains. Until the new production lines are fully operational, the company expects periodic availability constraints for the brand.
Comments (0)
No comments yet. Be the first!